WHITE PAPER: “Part 2: Optimization of Specialty Drug Costs Under the Medical Benefit”
RJ Health’s Senior Vice President of Clinical Analytics, Todd Cooperman (PharmD, MBA, RPh), has written this informative white paper on the optimization of specialty drug costs under the medical benefit. This is Part 2.
What does the white paper include?
In Part 2 of “Optimization of Specialty Drug Costs Under the Medical Benefit”, learn how the use of proper tools, modest policy adjustments, and straight-forward network engagement tactics helps organizations achieve various levels of savings.
In addition, through intensive analytics, a plan can reach a 6 to 12 percent savings within their medical specialty drug spend.